AFP Level Chart for Liver Cancer and Hepatocellular Carcinoma: Thresholds, Ranges, and False Positives

The AFP level chart for liver cancer centers on one number: 400 ng/mL. An alpha-fetoprotein above 400 ng/mL in a patient with a liver mass and cirrhosis is treated as diagnostic of hepatocellular carcinoma (HCC), and no biopsy is required per the 2018 AASLD guidelines. Below that line, AFP alone cannot rule cancer in or out. Roughly 20 to 30 percent of confirmed HCC cases never raise AFP at all, so the chart is a risk-stratifying tool, not a screening verdict. Normal is under 10 ng/mL; 10 to 200 ng/mL is the ambiguous zone.

What AFP Actually Measures and Why Tumors Raise It

Alpha-fetoprotein is a 70-kilodalton fetal serum protein, produced in large quantities by the fetal yolk sac and liver. After birth, production collapses. Adult blood levels sit near zero, typically under 10 to 20 ng/mL depending on the assay. The gene that encodes AFP is silenced in mature hepatocytes but reactivated in malignant transformation.

Why does a tumor restart an embryonic program? HCC cells dedifferentiate. They lose mature liver functions such as albumin synthesis and regain fetal markers. AFP reactivation tracks with the Wnt/beta-catenin pathway, which is mutated in 30 to 40 percent of HCCs. Tumors with beta-catenin activation tend to produce higher AFP. Tumors driven by other pathways, such as those with TERT promoter mutations alone, may produce none.

This mechanism explains the central quirk of every AFP chart. AFP is a marker of tumor biology, not tumor burden. A 2 cm tumor with the right mutation can dump 5,000 ng/mL into circulation. A 12 cm tumor with a non-secretory phenotype can sit at 6 ng/mL. In plain terms: AFP tells you what kind of cancer cell is growing, not just how much of it exists.

Two confounders complicate the readout. First, roughly 10 to 20 percent of healthy adults carry a benign hereditary elevation, usually 10 to 25 ng/mL, from a common genetic variant. Second, regenerating liver tissue also makes AFP, which is why hepatitis flares and cirrhosis raise it without cancer.

The AFP Level Chart: Ranges and Interpretations

The chart below maps typical serum values to their usual clinical interpretation. Ranges are approximate and assay-dependent; different lab platforms vary by 10 to 20 percent at the same concentration.

The 400 ng/mL cutoff is the most cited threshold in the literature. It comes from validation studies showing roughly 95 percent specificity for HCC when combined with a mass on imaging. At that level, the false-positive rate drops low enough that tissue sampling adds risk without adding information.

A second threshold matters for surveillance. A level that doubles over 4 to 6 weeks is treated as concerning even if it stays under 400 ng/mL. Trend carries more weight than any single reading, because a stable 250 ng/mL from chronic cirrhosis behaves very differently from a level climbing from 80 to 250 in two months.

Sensitivity and specificity: what the numbers hide

The headline sensitivity of AFP for HCC is often quoted at 60 percent at the 20 ng/mL cutoff. That single number obscures a sharper trade-off. Per the 2011 HALT-C cohort analysis (Lok et al.), lowering the cutoff to 10 ng/mL raises sensitivity but drops specificity into the 60s. Raising it to 200 ng/mL recovers specificity above 90 percent but misses roughly half of tumors under 3 cm.

The lesson is that AFP is a poor stand-alone screening test for early cancer. It performs well as a diagnostic adjunct once a mass is seen. This is why ultrasound remains the backbone of surveillance for at-risk patients, with AFP added rather than substituted.

AFP in cirrhosis and hepatitis: the false-positive problem

A cirrhotic liver is a regenerating liver, and regenerating hepatocytes make AFP. In a hepatitis B flare, levels can spike to 100 to 300 ng/mL and fall back to baseline within weeks. Up to 30 percent of patients with chronic hepatitis C and active cirrhosis show modest elevations in the 10 to 50 range with no tumor.

This produces a diagnostic trap. A cirrhotic patient with an AFP of 180 ng/mL and a 2 cm nodule may have either a small HCC or a regenerative nodule plus inflammation. Imaging characteristics, not the number, decide the case. Contrast-enhanced MRI showing arterial enhancement with venous washout confirms HCC regardless of the AFP value.

A non-obvious caveat: some HCCs secrete AFP only intermittently. A normal level one month does not exclude cancer the next. Serial monitoring every 3 to 6 months in high-risk patients catches the rising pattern that a single value misses.

Non-secretor HCC and other edge cases

The most underappreciated fact in the AFP chart is that a large fraction of liver cancers never touch it. Studies place the non-secretor rate at 20 to 30 percent of HCCs. These tumors are invisible to AFP surveillance entirely, which is why professional bodies never rely on AFP alone.

• Fibrolamellar HCC, a variant striking younger patients without cirrhosis, is AFP-negative in the majority of cases.
• Small tumors under 2 cm often fall below detection thresholds.
• Poorly differentiated tumors can lose AFP expression as they dedifferentiate further.
• Certain rare variants produce AFP that the assay fails to recognize due to glycosylation differences.
• Post-treatment, AFP can fall while imaging still shows viable tumor.

Each of these is a reason a normal AFP with a suspicious lesion demands imaging, not reassurance. The chart maps probability, not certainty.

AFP during and after treatment: the response timeline

AFP is highly useful as a treatment-response marker, because it reflects secretory activity and falls with a half-life of about 5 to 7 days once the tumor is removed or destroyed. The table below outlines the typical expected course.

A post-surgical AFP that never normalizes is a red flag for microscopic residual disease even when the scan looks clean. Conversely, a transient bump in the first 2 weeks after ablation or embolization can reflect tumor-cell death releasing stored protein, not progression. That pitfall trips up both patients and clinicians who read a single post-procedure number in isolation.

What to actually do with an AFP result

The chart is a starting map, not an answer. Concrete actions:

• If AFP is under 10 ng/mL and imaging is clean, continue standard surveillance at 6-month intervals if you have cirrhosis or chronic hepatitis B.
• If AFP is 10 to 200 ng/mL, get a contrast-enhanced CT or MRI of the liver and repeat AFP in 4 to 6 weeks to establish a trend.
• If AFP exceeds 400 ng/mL with a mass and cirrhosis, expect a diagnosis of HCC without biopsy and move to staging (BCLC or similar).
• If AFP is normal but a lesion is present, trust the imaging; non-secretor tumors are common.
• Keep every AFP result in one place so the trend, not the single value, drives decisions.
• After treatment, recheck AFP at 1 and 3 months, then every 3 to 6 months to catch recurrence early.

Limitations of AFP as a single marker

AFP cannot stand alone for three reasons. It lacks sensitivity for small and non-secretory tumors. It lacks specificity in inflamed livers. And it varies between lab assays, so results from different platforms are not directly interchangeable. A level of 20 on one assay may read 16 or 25 on another.

This is why modern practice pairs AFP with the GALAD score, which combines gender, age, AFP, AFP-L3, and DCP (des-gamma-carboxy prothrombin). GALAD lifts sensitivity for early HCC above 70 percent, well beyond AFP alone. Per the 2018 AASLD guidance, AFP remains an adjunct to imaging, never a replacement.

The honest reading of the AFP chart is probabilistic. It tells you when to worry harder and when to relax, but the decisive evidence for liver cancer always comes from a contrast-enhanced scan showing the tumor's blood-flow signature. A charted number informs that decision; it does not make it.